Skip to main
SGMO
SGMO logo

Sangamo Therapeutics (SGMO) Stock Forecast & Price Target

Sangamo Therapeutics (SGMO) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 31%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Sangamo Therapeutics Inc. has significantly enhanced the estimated value of its SIFTER/ZFP platform related to its neurology pipeline, now valued at $7 per share, indicating strong potential for transformational improvements in chronic neuropathic pain treatments. The probability of success for its isa-vec program has increased to 85%, attributed to stronger regulatory positioning, reflecting high investor confidence in the program's viability; however, revenues have been risk-adjusted by 45% due to collaboration terms, maintaining its valuation at $4 per share. Furthermore, the company's commitment to integrating sustainability into its strategy suggests a forward-looking approach, positioning Sangamo for long-term growth while addressing essential stewardship principles within the healthcare ecosystem.

Bears say

Sangamo Therapeutics Inc faces a negative outlook primarily due to its unpredictability in future revenues and expenses, compounded by its non-revenue-generating status, which raises concerns about financial sustainability. The company is currently experiencing significant challenges, including a net loss of $23 million, workforce reductions, and the pausing of late-stage pipeline projects, highlighting operational and financial distress. Additionally, risks related to clinical execution, regulatory uncertainties, and competitive pressures further exacerbate uncertainties regarding the potential for recovery and growth in the company's financial performance.

Sangamo Therapeutics (SGMO) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 31% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sangamo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sangamo Therapeutics (SGMO) Forecast

Analysts have given Sangamo Therapeutics (SGMO) a Buy based on their latest research and market trends.

According to 16 analysts, Sangamo Therapeutics (SGMO) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.66, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.66, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sangamo Therapeutics (SGMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.